Company intelligence / Profile preview

Biomix Network

Navi Mumbai, Maharashtra, India

Ownership: Private
Development stage: Other

Overview

Biomix Network has developed Receptol, a nano-biotech immune modulator and broad-spectrum antiviral. A completed Phase 3 trial demonstrated efficacy and safety as a stand-alone monotherapy for HIV/AIDS. Receptol is used in India and was distributed during pandemics such as Swine flu, with expanded claims including immune enhancement and applications for cancer, viral, and autoimmune indications[1][2][4].

Therapeutic areas: ImmunologyRheumatologyInfectious DiseasesGastroenterologyPulmonologyOncology
Modalities: Synthetic peptideNano-biotechnologySmall molecule
Industry: Biotech

Partnerships

Indian Council of Medical Research (ICMR)National AIDS Control Organization (WHO India)Department of Science & Technology (India)

Beyond the preview

Go deeper on Biomix Network.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Biomix Network.

Explore the full profile